Latest News
Ocugen, Inc.
- Ocugen Inc Estimates – XETR:2H51
- Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
- Ocugen moves OCU410 gene therapy for geographic atrophy into Phase 3 trial
- Ocugen licenses OCU400 gene therapy to Roots Pharmaceutical for MENA region
- Ocugen (OCGN) Licenses Gene Therapy OCU400 for MENA Region in Ne
- Ocugen licenses retinitis pigmentosa gene therapy to MENA region
- Ocugen CEO Shankar Musunuri sells $499,691 of company stock
- Ocugen to present novel gene therapy platform at major 2026 ophthalmology conferences
- Ocugen Row Revived as Third Cir. Dumps Investor Materiality Rule
- Ocugen receives provisional approval for gene therapy in Bahamas
- Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
- Ocugen receives provisional approval for OCU400 gene therapy in the Bahamas
Headlines from the last 30 days, linking to the original publishers. See all market news →